ArticleJournal of translational medicine2022

Ruxolitinib suppresses liver fibrosis progression and accelerates fibrosis reversal via selectively targeting Janus kinase 1/2.

Zhenghui Song et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.